高级检索
当前位置: 首页 > 详情页

Overexpression of miR-874 enhances chemosensitivity of glioma cells to temozolomide by the oncogenic STAT3 pathway

| 导出 |

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Tianjin Med Univ, Grad Sch, Tianjin, Peoples R China [2]Hebei Univ,Affiliated Hosp,Dept Neurosurg,Baoding,Hebei,Peoples R China [3]Tianjin Huanhu Hosp, Tianjin Neurol Inst, Tianjin Key Lab Cerebral Vasc & Neurodegenerat Di, 6 Jizhao Rd, Tianjin 300350, Peoples R China [4]Tianjin Med Univ, Dept Lab, Tianjin, Peoples R China
出处:
ISSN:

关键词: Glioblastoma MicroRNAs STAT3 transcription factor apoptosis cell migration assays chemotherapy adjuvant

摘要:
MicroRNAs, small non-coding RNAs (21-23 nt in length), are known for regulating carcinogenesis and tumor progression in glioma. MicroRNA-874 (miR-874) has shown play an important role in many human cancers as tumor suppressors. Our previous studies found that miR-874 reduced in glioma tissue and overexpression of miR-874 inhibits glioma cell proliferation and induces apoptosis. However, the biological functions of miR-874 in chemotherapy sensitivity enhancing effect have not been elucidated completely. The present study evaluated the biological function and mechanism of miR-874 in chemotherapy sensitivity enhancing effect in glioma. Our results revealed that the cell proliferation and migration were decreased, cell apoptosis was induced, and the mitochondrial membrane potential was also declined in glioma cells treated with miR-874 with temozolomide (TMZ). And miR-874 with TMZ can reduce the expression level of migration related protein MMP-2 and MMP-9, down-regulate the expression level of Bcl-2 and induce the expression level of Bax. More importantly, miR-874 with TMZ reduced the expression level of STAT3 protein and inhibited STAT3 phosphorylation. Our results demonstrated that overexpression of miR-874 potentiates chemosensitivity of glioblastoma to TMZ by the oncogenic STAT3 pathway, which might provide novel strategies for clinical treatment.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 病理学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 病理学
JCR分区:
出版当年[2017]版:
Q3 PATHOLOGY Q4 ONCOLOGY
最新[2023]版:
Q3 PATHOLOGY Q4 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]Tianjin Med Univ, Grad Sch, Tianjin, Peoples R China [2]Hebei Univ,Affiliated Hosp,Dept Neurosurg,Baoding,Hebei,Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:15101 今日访问量:2 总访问量:962 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持:重庆聚合科技有限公司 地址:保定市莲池区裕华东路212号